Second phase III study of ALLN-177 enteric hyperoxaluria
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs ALLN 177 (Primary)
- Indications Hyperoxaluria
- Focus Registrational; Therapeutic Use
- Acronyms URIROX-2
- Sponsors Allena Pharmaceuticals
- 09 Mar 2018 New trial record
- 06 Mar 2018 According to an Allena Pharmaceuticals media release, the company expects to initiate URIROX-2 in the second half of 2018.
- 06 Mar 2018 According to an Allena Pharmaceuticals media release, the company is working with the FDA to finalize the design of this trial.